[{"data":1,"prerenderedAt":246},["ShallowReactive",2],{"content-route-/en/research/candida-biofilm-candidemia-mortality-2024":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":181,"alternates":237},"target","/en/research/candida-biofilm-candidemia-mortality-2024","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":66,"body":70},"Candida biofilm and mortality in cancer patients with candidemia","A retrospective Peruvian cancer-center cohort linked in-vitro Candida biofilm levels with 30-day in-hospital mortality; the study does not establish cause or change care.","2026-10-09","Added a contextual summary of a retrospective oncology candidemia cohort; in-vitro isolate findings do not establish causation or change practical guidance.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":42,"limitations":49,"practicalChange":65},"villanueva-cotrina-biofilm-candidemia-mortality-2024","Retrospective single-center observational cohort with in-vitro Candida-isolate XTT biofilm assay","Hospitalized patients with cancer and Candida-positive blood cultures at Peru's National Oncology Reference Center in Lima; the analyzed cohort included children and adults.","The report describes 148 Candida-positive cultures from 137 people, then analyzes 140 patients/cases without reconciling the unit discrepancy. Biofilm categories were no formation (34/140), low/medium (97/140), and high (9/140); treatment strata were 24 untreated and 116 treated.","contextual","This retrospective cohort adds a patient-outcome association in a defined invasive infection setting: in-vitro biofilm formation by blood-culture isolates was compared with 30-day in-hospital mortality among hospitalized oncology patients. The estimate for high-level formation came from only nine isolates, treatment was not assigned, and the study cannot show that a patient had a biofilm or that biofilm caused death. It does not test a diagnostic or treatment change.","/en/research/evidence/broad-candida-claims","The authors state that study activities were self-financed without organizational support. The acknowledgements separately note NIH Fogarty International Center program D43 TW007393 support for author AGL and the master's program, and a Belgian Development Agency–CTB grant for the master's program.","The authors declared no competing interests.","2024-10-12",[38,39,40,41],"The report says 148 Candida-positive cultures came from 137 people, then labels the final analytic set 140 patients (Table 1 calls them cases); it does not explain whether the 140 units are unique people or episodes. Tables report 65/140 (46.4%) all-cause in-hospital deaths by 30 days.","In-vitro biofilm was present in 106/140 cases: 34 had no formation, 97 had low/medium formation, and 9 had high formation. Deaths were 11/34 (32.3%), 48/97 (49.5%), and 6/9 (66.7%), respectively (p=0.033 across levels). Combining any biofilm versus none gave 54/106 (50.9%) versus 11/34 (32.3%) deaths (p=0.059).","Among 24 cases receiving neither antifungal nor antimicrobial therapy, 17/24 (70.8%) died. Table 4 reports 1/4 (25.0%) with no biofilm, 14/17 (82.3%) with low/medium biofilm, and 2/3 (66.7%) with high biofilm (p=0.049 across levels); 14/17 conventionally rounds to 82.4%. The abstract's first-day and biofilm-level descriptions conflict with the Results and tables; this summary uses the latter.","In the treated stratum, 48/116 (41.4%) died. For high versus no biofilm, the crude hazard ratio was 3.92 (95% CI 1.22–12.57; p=0.022) and the adjusted hazard ratio was 6.59 (95% CI 1.87–23.24; p=0.003), adjusted for age group, comorbidities, and emergency admission. Low/medium versus no biofilm had an adjusted hazard ratio of 1.30 (95% CI 0.62–2.75; p=0.492).",{"appliesTo":43,"doesNotApplyTo":46},[44,45],"Group-level association between an in-vitro XTT biofilm phenotype of Candida blood isolates and 30-day in-hospital mortality in this hospitalized oncology cohort in Lima, Peru.","The treated-stratum survival estimates for the 116 cases receiving antifungal and/or antimicrobial therapy.",[47,48],"A biofilm measurement in a patient's body; individual diagnosis, prognosis, or cause of death; people without cancer or other candidemia settings; or outpatient symptoms.","Benefit or harm from antifungal treatment, antimicrobials, or biofilm-disrupting products; diagnostic performance; or broad intestinal, mucosal, or whole-body Candida claims.",[50,53,56,59,62],{"finding":51,"limitation":52},"The report describes cultures from 137 people but an analytic set of 140 patients/cases.","It does not reconcile whether the analysis counts unique people or candidemia episodes, so the unit of analysis is uncertain.",{"finding":54,"limitation":55},"Only 9/140 cases had high-level biofilm formation, and 24/140 received neither antifungal nor antimicrobial therapy.","The estimates are imprecise, the untreated stratum was too small for multivariable analysis, and separate treatment-stratum analyses reduced power.",{"finding":57,"limitation":58},"The high-versus-none adjusted hazard ratio was estimated only among the 116 treated cases.","Treatment was not randomized, the analysis may be confounded by illness severity and treatment timing, and the estimate does not establish that biofilm or treatment caused death.",{"finding":60,"limitation":61},"XTT testing classified biofilm formation by cultured isolates in a laboratory assay.","It did not measure biofilm in a patient, validate a diagnostic test, or test an intervention. The single-center retrospective cancer cohort, missing severity and cancer-stage data, and unavailable catheter-removal data also limit applicability.",{"finding":63,"limitation":64},"The abstract's mortality description differs from the detailed Results and Tables 3–4.","It presents 81.0% as first-day mortality among 21 untreated patients; the Results and Table 3 show 17/21 day-one deaths occurred in the untreated group, while all deaths in that 24-case group were 17/24 (70.8%). The abstract also swaps the low/medium and high untreated mortality percentages; Table 4 gives 14/17 (reported 82.3%; conventionally 82.4%) for low/medium and 2/3 (66.7%) for high. The summary follows the detailed Results and tables.","No practical change. The in-vitro observational association does not establish in-vivo biofilm, causation, individual risk, diagnostic value, or treatment benefit and is not a reason to change care.",[67],{"group":68,"route":33,"label":69},"evidence","Evidence map: broad Candida claims",{"type":71,"value":72,"toc":177},"minimark",[73,81,87,96,105,120,126,135,141,147,153],[74,75,77],"content-section",{"section-key":10,"title":76},"Bottom line",[78,79,80],"p",{},"In this retrospective cohort from a Peruvian cancer referral center, higher in-vitro biofilm levels among Candida blood isolates were associated with higher 30-day in-hospital mortality across three categories. The binary comparison of any biofilm versus none was not statistically significant, and only nine cases had high-level formation. The study does not show that biofilm caused death or change care.",[74,82,84],{"section-key":11,"title":83},"Why this source matters",[78,85,86],{},"This study connects an isolate phenotype measured in the laboratory with a patient outcome in a defined invasive infection setting. It adds context about candidemia among hospitalized patients with cancer, while keeping the in-vitro assay distinct from biofilm in a person's body and from a treatment effect.",[74,88,90,93],{"section-key":12,"title":89},"Study and population",[78,91,92],{},"The retrospective single-center cohort included hospitalized patients with cancer and Candida-positive blood cultures at the Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru. Cultures and records covered June 2015 through October 2017. The cohort included children: 28/140 cases were ages 0–15, 82/140 were ages 16–59, and 30/140 were 60 or older.",[78,94,95],{},"The report says 148 Candida-positive cultures came from 137 people, then describes a final sample of 140 “patients”; Table 1 labels the 140 as “cases.” It does not clearly reconcile whether the analytic units were unique people or candidemia episodes. Repeated candidemia less than a month after an earlier episode was excluded.",[74,97,99,102],{"section-key":13,"title":98},"What was tested",[78,100,101],{},"Researchers used a laboratory XTT-reduction assay on Candida isolates from blood cultures. Optical-density thresholds classified isolates as having no biofilm (\u003C0.1), low (0.1–0.25), medium (0.26–0.5), or high (>0.5) formation; low and medium were combined. This was an in-vitro isolate phenotype, not a measurement of biofilm in a patient or a routine diagnostic test.",[78,103,104],{},"The outcome was all-cause in-hospital death within 30 days of candidemia diagnosis. Patients alive beyond 30 days or discharged were censored as survivors. Treatment was not assigned; analyses were split between 24 cases receiving neither antifungal nor antimicrobial therapy and 116 receiving at least one.",[74,106,108,111,114,117],{"section-key":14,"title":107},"Results",[78,109,110],{},"Across the 140 analyzed cases, 65 (46.4%) died in hospital within 30 days. Biofilm formation was classified as absent in 34/140 cases, low/medium in 97/140, and high in 9/140. Deaths by category were 11/34 (32.3%), 48/97 (49.5%), and 6/9 (66.7%); the three-level comparison had p=0.033. For any biofilm versus none, deaths were 54/106 (50.9%) versus 11/34 (32.3%), with p=0.059.",[78,112,113],{},"Among the 24 cases receiving neither antifungal nor antimicrobial therapy, 17/24 (70.8%) died. Table 4 reports deaths in 1/4 cases with no biofilm (25.0%), 14/17 with low/medium biofilm (82.3%), and 2/3 with high biofilm (66.7%) (p=0.049 across levels). The table's 14/17 percentage is printed as 82.3%; conventional rounding to one decimal gives 82.4%.",[78,115,116],{},"In the treated stratum, 48/116 (41.4%) died. For high biofilm versus none, the crude hazard ratio was 3.92 (95% CI 1.22–12.57; p=0.022) and the adjusted hazard ratio was 6.59 (95% CI 1.87–23.24; p=0.003), adjusted for age group, comorbidities, and emergency admission. Low/medium versus none had an adjusted hazard ratio of 1.30 (95% CI 0.62–2.75; p=0.492). The high-level estimate is based on only nine cases in the full cohort and is imprecise.",[78,118,119],{},"The abstract's untreated mortality descriptions conflict with the detailed Results and tables. It presents 81.0% as first-day mortality among 21 untreated patients; Results and Table 3 show 17/21 of all day-one deaths were in the untreated group, while total deaths in the 24-case untreated group were 17/24 (70.8%). The abstract also reverses the low/medium and high mortality percentages. Table 4 reports low/medium as 14/17 (82.3% printed; 82.4% by conventional rounding) and high as 2/3 (66.7%); those detailed table values are used here.",[74,121,123],{"section-key":15,"title":122},"Applicability",[78,124,125],{},"The findings concern an association between in-vitro biofilm formation by Candida blood isolates and in-hospital mortality among hospitalized cancer patients with candidemia at one referral center in Lima. They do not estimate individual risk or apply directly to people without cancer, other candidemia settings, or outpatient symptoms. The study does not establish a biofilm in a patient or show that a biofilm phenotype caused the outcome.",[74,127,129,132],{"section-key":16,"title":128},"Limitations",[78,130,131],{},"This was a retrospective, single-center cohort, and the report does not reconcile its 137 people and 140 analytic patients/cases. Only 9/140 cases had high-level formation and 24 were untreated; the untreated group was too small for multivariable analysis, and splitting the survival analyses by treatment reduced power. The treated-stratum association is observational, potentially confounded by illness severity and treatment timing, and cannot establish a treatment effect.",[78,133,134],{},"The XTT assay characterized isolates in vitro, not biofilm in a patient. The authors lacked cancer-stage/status and uniform severity measures; APACHE II was unsuitable for many participants, and catheter-removal data were unavailable. The abstract also conflicts with the detailed Results and Tables 3–4 about first-day deaths and untreated biofilm-level percentages; this summary follows the detailed tables and notes the percentage-rounding discrepancy.",[74,136,138],{"section-key":17,"title":137},"Contribution to the evidence",[78,139,140],{},"Contextual. The cohort adds a patient-outcome association from a defined invasive infection setting. The high-level estimate is based on nine isolates, is imprecise, and comes from an observational treatment stratum. It adds context to the evidence map without establishing in-vivo biofilm, causation, or a new diagnostic or therapeutic action.",[74,142,144],{"section-key":18,"title":143},"Practical change",[78,145,146],{},"No practical change. The study tested neither a diagnostic method nor an intervention. Its laboratory isolate association is not a reason to add a biofilm-disrupting product or change candidemia treatment.",[74,148,150],{"section-key":19,"title":149},"Funding and conflicts",[78,151,152],{},"The authors state that study activities were self-financed without organizational support. Acknowledgements separately note support from NIH Fogarty International Center program D43 TW007393 for author AGL and the master's program, and a Belgian Development Agency–CTB grant for the master's program. The authors declared no competing interests.",[74,154,156],{"section-key":20,"title":155},"Source",[78,157,158,165,166,170,171,176],{},[159,160,164],"a",{"href":161,"rel":162},"https://pmc.ncbi.nlm.nih.gov/articles/PMC11470705/",[163],"nofollow","Read the original publication"," (published 12 October 2024; ",[167,168,169],"em",{},"BMC Infectious Diseases",". 2024;24:1145). DOI: ",[159,172,175],{"href":173,"rel":174},"https://doi.org/10.1186/s12879-024-10044-5",[163],"10.1186/s12879-024-10044-5",".",{"title":178,"searchDepth":179,"depth":179,"links":180},"",2,[],{"sources":182,"claims":187,"safety":236},[183],{"sourceId":27,"title":184,"canonicalId":185,"canonicalUrl":161,"publisher":169,"sourceType":186,"publicationDate":36,"lastChecked":24},"Biofilm formation and increased mortality among cancer patients with candidemia in a Peruvian reference center","PMID:39395965; DOI:10.1186/s12879-024-10044-5","observational-study",[188],{"claimId":189,"exactClaim":190,"outcome":191,"population":192,"verdict":193,"evidenceLevel":194,"rationale":195,"safetyStatus":196,"evidenceAsOf":24,"lastUpdated":24,"status":197,"changeHistory":198,"sources":207},"candida-biofilms-have-defined-clinical-boundaries","Candida can form biofilms in defined device-associated and mucosal infections, but demonstrating this biology in those settings does not establish a hidden intestinal biofilm or broad multisystem Candida syndrome in a person with nonspecific symptoms.","presence and clinical relevance of Candida biofilm in a defined infection, without extrapolation to an unvalidated broad syndrome","people with microbiologically and clinically defined Candida infection, especially device-associated candidiasis, compared with otherwise stable people attributing nonspecific symptoms to an unconfirmed intestinal or whole-body Candida biofilm","supported","moderate","CDC catheter guidance and the IDSA candidiasis guideline recognize Candida adherence, extracellular matrix, reduced antimicrobial susceptibility, and the clinical importance of source control in defined device-associated infection. Current biofilm synthesis also describes mucosal and device models. A prospective single-center cohort found higher in-vitro crystal-violet biomass among vaginal isolates from the group with recurrent vulvovaginal candidiasis (RVVC), while XTT activity and a selected confocal-area comparison were not statistically significant; these isolate assays do not measure vaginal biofilm in vivo. A retrospective oncology-center candidemia cohort adds a patient-outcome association for high-level in-vitro biofilm in the treated subgroup (adjusted HR 6.59, 95% CI 1.87-23.24), but only nine high-level isolates were present overall, the binary comparison was not significant, and the paper's patient/case denominator is unclear. This observational subgroup result does not establish causation or a treatment effect. None of these sources validates nonspecific symptoms as a test for an intestinal biofilm or permits device-associated findings to be transferred to a broad outpatient syndrome.","usual-cautions","active",[199,204],{"date":24,"summary":200,"previousVerdict":193,"currentVerdict":193,"previousEvidenceLevel":194,"currentEvidenceLevel":194,"previousSafetyStatus":196,"currentSafetyStatus":196,"practicalActionChanged":201,"sourceIds":202},"Reviewed the whole source set after adding the prospective vaginal-isolate cohort; higher in-vitro crystal-violet biomass adds defined mucosal context, while the XTT and selected CLSM comparisons were not significant. Verdict, evidence level, safety status, and practical action remain unchanged.",false,[203],"diaz-navarro-candida-biofilm-rvvc-2025",{"date":24,"summary":205,"previousVerdict":193,"currentVerdict":193,"previousEvidenceLevel":194,"currentEvidenceLevel":194,"previousSafetyStatus":196,"currentSafetyStatus":196,"practicalActionChanged":201,"sourceIds":206},"Added a retrospective oncology-center candidemia cohort with an imprecise high-biofilm mortality association limited to the treated subgroup; the overall binary comparison was not significant and only nine cases had high-level biofilm. This adds invasive-infection context without establishing causation or changing the verdict, evidence level, safety status, or practical action.",[27],[208,216,222,229,235],{"title":209,"canonicalId":210,"canonicalUrl":211,"publisher":212,"sourceType":213,"publicationDate":214,"lastChecked":215},"Background Information: Pathogenesis — Guidelines for the Prevention of Intravascular Catheter-Related Infections","CDC catheter guideline pathogenesis","https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/pathogenesis.html","US Centers for Disease Control and Prevention","guideline","2011-01-01","2026-07-15",{"title":217,"canonicalId":218,"canonicalUrl":219,"publisher":220,"sourceType":213,"publicationDate":221,"lastChecked":215},"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","2016-02-15",{"title":223,"canonicalId":224,"canonicalUrl":225,"publisher":226,"sourceType":227,"publicationDate":228,"lastChecked":215},"Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology","PMID:41524898; DOI:10.1007/s00284-025-04713-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC12795885/","Current Microbiology","other","2026-01-12",{"title":230,"canonicalId":231,"canonicalUrl":232,"publisher":233,"sourceType":186,"publicationDate":234,"lastChecked":24},"New insights in the role of Candida biofilm in the pathogenesis of recurrent vulvovaginal candidiasis: a prospective clinical study","PMID:40212387; DOI:10.3389/fmicb.2025.1566171","https://doi.org/10.3389/fmicb.2025.1566171","Frontiers in Microbiology","2025-03-27",{"title":184,"canonicalId":185,"canonicalUrl":161,"publisher":169,"sourceType":186,"publicationDate":36,"lastChecked":24},[],[238,241,244],{"rel":239,"hreflang":6,"href":240},"alternate","https://candipedia.org/en/research/candida-biofilm-candidemia-mortality-2024/",{"rel":239,"hreflang":242,"href":243},"pl-PL","https://candipedia.org/pl/research/biofilm-kandydemia-smierc-2024/",{"rel":239,"hreflang":245,"href":240},"x-default",1794951393367]